CNBC May 30, 2024
Sophie Kiderlin

Key Points

– The rise of weight loss drugs means consumers’ nutritional needs are “shifting,” Nestle CEO Mark Schneider told CNBC’s Silvia Amaro.

– Nestle is looking to capitalize on the popularity of the GLP-1 drugs with its “ambitious goal to push the healthier products,” the CEO said.

– The Swiss food and beverage giant is set to launch frozen food products targeted at GLP-1 weight loss drug users called Vital Pursuit later this year.

The meteoric rise of weight loss drugs means consumers’ nutritional needs are “shifting” which provides new opportunities for food companies, Nestle CEO Mark Schneider told CNBC.

Investors were initially concerned about the popularity of GLP-1 drugs such as Wegovy and Ozempic as it was assumed...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Retailer
After slow start, ACA enrollment takes off
FDA updates definition of 'healthy'
CMS says record 16.6 million have signed up for Jan. 1 Marketplace coverage
How America Lost Control of the Bird Flu, Setting the Stage for Another Pandemic
How Mount Sinai doubled its hospital-at-home program

Share This Article